Centaurus Financial Inc. Purchases 1,700 Shares of AstraZeneca PLC (NASDAQ:AZN)

Centaurus Financial Inc. lifted its position in AstraZeneca PLC (NASDAQ:AZN) by 72.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,037 shares of the company’s stock after purchasing an additional 1,700 shares during the quarter. Centaurus Financial Inc.’s holdings in AstraZeneca were worth $315,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in AZN. Martin Investment Management LLC increased its stake in AstraZeneca by 2.8% during the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock worth $22,571,000 after acquiring an additional 7,615 shares during the last quarter. Integrated Advisors Network LLC boosted its position in shares of AstraZeneca by 46.6% during the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after buying an additional 13,860 shares during the period. Creative Planning boosted its position in shares of AstraZeneca by 8.0% during the third quarter. Creative Planning now owns 224,751 shares of the company’s stock valued at $17,510,000 after buying an additional 16,692 shares during the period. Northcape Wealth Management LLC purchased a new position in shares of AstraZeneca during the second quarter valued at approximately $269,000. Finally, Cetera Advisors LLC boosted its position in shares of AstraZeneca by 124.5% during the first quarter. Cetera Advisors LLC now owns 98,262 shares of the company’s stock valued at $6,657,000 after buying an additional 54,488 shares during the period. 20.35% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on AZN. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. TD Cowen increased their target price on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $89.75.

AstraZeneca Stock Up 1.3 %

AstraZeneca stock opened at $67.20 on Thursday. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The stock has a market capitalization of $208.36 billion, a price-to-earnings ratio of 32.15, a PEG ratio of 1.22 and a beta of 0.47. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The business has a fifty day moving average price of $72.72 and a 200-day moving average price of $77.58.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business’s quarterly revenue was up 18.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.87 EPS. Equities research analysts forecast that AstraZeneca PLC will post 4.1 EPS for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.